中國在世界製造過程中的地位（2023）：中國新地位與現有地區製造能力和產出比較（第二版）

本報告分析了快速增長和變化的中國生物製藥行業的趨勢信息和未來前景，並與之前發布的年度報告（《生物製藥產能和產量分析》）進行了比較。 □利用匯總數據，我們認為新的市場趨勢和未來機會。

特殊細分：分析與意見部分行業分析師的評論

本報告比較了中國和世界其他地區生物製藥製造行業的分析結果，提供了過去趨勢的信息，同時展望了整個行業的前景。

• 由行業專家審核
• 專家分析
• 所有 66 頁
• 涵蓋所有 14 個行業
• 主要人物

分析範圍

• 生物製藥製造的主要趨勢（2023 年）
• 初級重組蛋白的平均成本
• 單克隆抗體 (mAb) 的抗體滴度：按生產規模分類
• 當前產能利用率
• 當前產能限制
• 下游生物加工步驟對整體生產能力造成限制
• 避免產能受到重大限制的關鍵領域
• 未來 12 個月預算和資金比率的變化
• 過去 12 個月為降低總體生物工藝成本而採取的行動
• 一次性/一次性生物製造系統
• 未來 12 個月製造外包支出的變化
• 其他

An Invaluable Resource for Trends & Analysis

An in-depth review of emerging trends and opportunities, with comparative, aggregated data from BioPlan's 20^th Annual Report and Survey of Biopharmaceutical Manufacturing Capacity and Production, providing trend information and relevant new in-depth insights into the rapidly growing and changing Chinese biologics industry.

SPECIAL SEGMENTS: Industry Reviewers' Comments in Analysis and Implications Sections.

This Report compares biomanufacturing industry insights in China with the rest of the world, and allows us to provide an insight into historical trends while keeping an eye on the outlook of the industry overall.

• Reviewed by Industry Experts
• Subject Matter Expert analysis
• 66 Pages
• 14 Segments covered
• Key Graphs and Tables

COVERAGE:

• Key Biomanufacturing Trend of 2023

• Average Cost for Primary Recombinant Protein

• Titer Ranges for mAbs at Various Production Scales

• Current Percent of Total Capacity for Facility Operation

• Capacity Constraints Today

• Downstream Bioprocessing Steps Creating Overall Capacity Constraints

• Important Areas to Avoid Significant Capacity Constraints

• Budget and Funding Percentage Changes over the Next 12 Months

• Actions to Reduce Overall Bioprocessing Costs During Past 12 Months

• Single-use/Disposable Biomanufacturing Systems

• Change in Spending on Outsourcing for Manufacturing Next 12 Months

• And More!